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The effects of dietary cholesterol on brain amyloid
precursor protein (APP) processing were examined us-
ing an APP gene-targeted mouse, genetically humanized
in the amyloid b-peptide (Ab) domain and expressing
the Swedish familial Alzheimer’s disease mutations.
These mice express endogenous levels of APP holopro-
tein and abundant human Ab. Increased dietary choles-
terol led to significant reductions in brain levels of se-
creted APP derivatives, including sAPPa, sAPPb, Ab1–
40, and Ab1–42, while having little to no effect on cell-
associated species, including full-length APP and the
COOH-terminal APP processing derivatives. The
changes in levels of sAPP and Ab in brain all were neg-
atively correlated with serum cholesterol levels and lev-
els of serum and brain apoE. These results demonstrate
that secreted APP processing derivatives and Ab can be
modulated in the brain of an animal by diet and provide
evidence that cholesterol plays a role in the modulation
of APP processing in vivo. APP gene-targeted mice lack-
ing apoE, also have high serum cholesterol levels but do
not show alterations in APP processing, suggesting that
effects of cholesterol on APP processing require the
presence of apoE.
Alzheimer’s disease (AD)1 pathology includes extracellular
amyloid deposits, intracellular neurofibrillary tangles, synap-
tic loss, and neuronal death (for a review, see Ref. 1). Alter-
ations in the production or processing of APP have been impli-
cated in the etiology of at least some forms of AD (2, 3).
Multiple pathways for APP processing have been described,
including a nonamyloidogenic pathway in which a putative
a-secretase cleaves within the Ab domain (4, 5), resulting in
the formation of a secreted NH2-terminal fragment, sAPPa,
and a cell-associated 9-kDa COOH-terminal derivative. An-
other fraction of APP is processed along an amyloidogenic
pathway in which cleavage by a putative b-secretase at the
NH2 terminus of the Ab domain results in the formation of a
secreted NH2-terminal fragment, sAPPb (6), and a cell-associ-
ated 12-kDa COOH-terminal derivative that may be the imme-
diate precursor of Ab (7, 8). Cleavage of APP by both b-secre-
tase and g-secretase results in formation of Ab, 40 or 42 amino
acids in length (9, 10), that is found deposited in extracellular
amyloid plaques in the AD brain (1, 11).
In order to elucidate mechanisms of APP processing and Ab
generation in vivo, an animal model was developed by gene
targeting that converted the mouse Ab sequence to human and
incorporated the Swedish familial Alzheimer’s disease muta-
tions (12). Enhanced amyloidogenic APP processing by the
Swedish mutations, resulting in higher level Ab production has
been well documented in cell culture systems (13–15) and in
the APP gene-targeted mice (12). These mice are well suited for
investigating modulation of APP processing in vivo, because
brain Ab levels are nearly 10-fold above normal endogenous
levels, thereby reducing the stringency for assays to detect Ab,
particularly for the less abundant but more amyloidogenic 42-
residue form. Furthermore, proper developmental and tissue-
specific expression of APP and Ab is maintained in the gene-
targeted mice (12).
Here, we have examined the impact of dietary cholesterol
and apoE on APP processing and Ab levels using the APP
gene-targeted mice. Cholesterol is an integral component of all
eukaryotic cell membranes and is essential for normal cellular
functions including caveolae formation (16, 17) and covalent
modification of embryonic signaling proteins (18). Cholesterol
also dramatically affects physical properties of cell membranes
such as increasing ordering and rigidity and decreasing perme-
ability and lateral diffusion (19). Alterations in membrane lipid
and cholesterol content have been reported to modulate the
activities of intrinsic membrane enzymes (20–24). Cellular cho-
lesterol content arises either through intracellular synthesis or
by uptake of cholesterol through the low density lipoprotein
(LDL) receptor pathway (25). These pathways are tightly reg-
ulated by sterol regulatory element-binding proteins
(SREBPs), membrane-bound transcription factors whose pro-
teolytic cleavage and subsequent translocation to the nucleus
regulate transcription of multiple cholesterol homeostatic
genes (26). In the brain, apoE primarily directs the mobiliza-
tion and redistribution of cholesterol during membrane remod-
eling associated with the plasticity of synapses (27–31). The
apoE gene is a risk factor for sporadic and late onset AD
(32–38). Alterations in cholesterol metabolism have been re-
ported to occur with age (39–45) and have been implicated in
the pathogenesis of AD (46–49). Directly pertinent to APP
metabolism, cholesterol has been recently linked to decreased
release of secreted APP in cultured cells (50, 51). However,
neither of these studies presented data concerning the effects of
cholesterol on Ab production. We demonstrate that increased
dietary cholesterol lowers levels of secreted APP derivatives
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including sAPPa and sAPPb in mouse brain. Additionally, cho-
lesterol in the diet resulted in decreases in the levels of both
major secreted Ab forms, Ab1–40 and Ab1–42. The reported
effects of cholesterol on APP processing derivatives in brain
appeared to require the presence of apoE.
EXPERIMENTAL PROCEDURES
Animals and Diets—APP gene-targeted mice (APPnNLh/nNLh), wild-
type for apoE, containing a humanized Ab domain and bearing the
Swedish familial Alzheimer’s disease KM to NL mutations have been
described previously (12). Homozygous APPnNLh/nNLh mice, 210–408
days in age, were maintained for 8 weeks on a basal diet (number 5755C
Purina Test Diet), containing trace amounts (0.005%) of cholesterol and
10% fat or a high cholesterol diet (number 5801C Purina Test Diet)
containing 10% fat and 5% cholesterol. APP gene-targeted mice were
bred with apoE knockout (KO) mice to generate double homozygous
mice (APPNLh/NLh, ApoE2/2). APPNLh/NLh, ApoE2/2 (n 5 4) and APP
gene-targeted mice, wild-type for apoE, (APPNLh/NLh, ApoE1/1) (n 5 4),
each approximately 180 days old, fed a laboratory chow diet (Rodent
5001, Purina Mills Inc., St. Louis, MO) containing 0.027% cholesterol
and 4.5% fat, were used to compare the effect of the apoE genotype on
APP processing fragments in brain. Mice had access to the pelleted
diets and water ad libitum. All animals were sacrificed prior to analysis
by CO2 asphyxiation. Brains were removed, washed in saline, and
frozen at 270 °C prior to analysis.
Measurement of Serum and Tissue Total Cholesterol—Trunk blood
was collected at sacrifice from mice in a nonfasted state in order to avoid
potential complicating effects of food deprivation on APP metabolism.
Serum total cholesterol (TC) was measured using an enzymatic-colori-
metric assay (number 352, Sigma). To measure tissue total cholesterol
levels, liver, mouse half-brain, or dissected frontal cortices were homog-
enized in B buffer (20 mM Tris-HCl, 2 mM EGTA, 1 mM EDTA, 1 mM
benzamidine, 1 mM dithiothreitol, and 1 mM phenylmethylsulfonyl flu-
oride, pH 7.4). Lipids and cholesterol were extracted with 10 volumes of
a chloroform/methanol mix (2:1, v/v) as described previously (52). Dried
samples were resuspended in 400 ml of 2:1 (v/v) chloroform/methanol,
and aliquots were mixed with 1 ml of a 2% Triton X-100/chloroform
solution. Dried samples were resuspended in 0.5 ml of water, and total
cholesterol was determined using the enzymatic-colorimetric assay.
Antibodies—Monoclonal Ab 6E10, specific for the human Ab peptide
1–17 sequence, was obtained from Senetek (Maryland Heights, MO).
Immunoprecipitating rabbit polyclonal Ab 1153 was raised against
human Ab1–28 (53), and Ab 97 was raised against the 30 COOH-
terminal APP residues, APP741 to APP770 (APP770 coordinates) (12).
Rabbit polyclonal Ab 9 was directed against APP724 to APP747 (54)
and recognizes both the 12-kDa and 9-kDa COOH-terminal APP deriv-
atives (12). Rabbit polyclonal Ab 54 is specific for the last five amino
acids of Swedish sAPPb (SEVNL) (12, 55). Rabbit polyclonal Ab specific
for mouse apoE was obtained from BioDesign Inc. (Kennebunkport,
ME; number K23100R). The monoclonal Ab C4 (Boehringer Mannheim)
was used to detect mouse actin. An Ab40-selective polyclonal Ab was
used in the Ab40 ELISA (Quality Control Biochemicals, Hopkinton,
MA). All secondary antibodies (GAM-IgG and GAR-IgG) conjugated to
horseradish peroxidase were obtained from Bio-Rad or from Southern
Biotechnology Associates (Birmingham, AL).
Measurement of sAPP (sAPPa, Swedish sAPPb) and ApoE in Brain—
One-half brain or dissected frontal cortex was homogenized in 3 ml of B
buffer and centrifuged at 100,000 3 g for 1 h. Tris-soluble supernatant
fractions were removed and assayed for total protein concentration by
BCA assay (Pierce). Fifty mg of each extract was electrophoresed on 8%
Tris-Glycine SDS-polyacrylamide gels (Novex, San Diego, CA) and sub-
sequently transferred to nitrocellulose. For detection of sAPPa, blots
were incubated with 1:2000 Ab 6E10 followed by 1:2000 GAM-IgG
conjugated to horseradish peroxidase. For detection of Swedish sAPPb,
blots were incubated with 1:500 Ab 54 followed by 1:2000 GAR-IgG
conjugated to horseradish peroxidase. Ab C4 was used at 1:2000 to
detect actin in each brain extract for normalization. Enhanced chemi-
luminescence (ECL) was used as the detection reagent (Amersham
Pharmacia Biotech). To detect mouse brain apoE, 50 mg of Tris-soluble
extracts from half-brain or frontal cortex were electrophoresed on 10–
20% Tris-Tricine SDS-polyacrylamide gels and transferred to polyvi-
nylidene difluoride membrane. Membranes were incubated with 1:2000
anti-apoE Ab followed by 1:2000 GAR-IgG conjugated to horseradish
peroxidase and ECL as the detection reagent.
Measurement of Cell-associated APP (Full-length APP (flAPP), 12-
and 9-kDa Fragments)—Tris-insoluble pellets following 100,000 3 g
centrifugation of brains extracted with B buffer were washed with an
additional 3 ml of B buffer followed by sonication in 1 3 radioimmune
precipitation buffer (50 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, 1%
Triton X-100, 0.25% sodium deoxycholate, 0.1% SDS, 1 mM benzami-
dine, 0.05 mM leupeptin, 0.02 mM pepstatin A). Supernatants from
100,000 3 g spin were removed and assayed for total protein by BCA
assay. Radioimmune precipitation-soluble protein containing cell-asso-
ciated APP was immunoprecipitated with Ab 97 as described previously
(12). Immunoprecipitates were split equally and electrophoresed either
on 8% Tris-Glycine SDS-polyacrylamide or 16% Tris-Tricine SDS-poly-
acrylamide gels. For detection of flAPP, 8% gels were transferred to
nitrocellulose and subsequently incubated with Ab 6E10 (1:2000) fol-
lowed by 1:2000 GAM-IgG-conjugated to horseradish peroxidase and
ECL detection. For detection of the 12- and 9-kDa COOH-terminal APP
derivatives, 16% gels were transferred to polyvinylidene difluoride fol-
lowed by subsequent incubation with Ab 9 (1:500) and 1:2000 GAR-IgG
conjugated to horseradish peroxidase and ECL detection reagent. Ab C4
was used at 1:2000 to detect actin in each brain extract and was used for
normalization.
Measurement of Brain Ab—A sandwich ELISA that specifically de-
tects Ab1–40 (56), but not Ab17–40 or Ab1–42, was used on brain
samples. Frozen mouse half-brains were Dounce homogenized at a ratio
of 150 mg of tissue/ml of 70% (v/v) formic acid, homogenates were
centrifuged at 100,000 3 g for 1 h, and the supernatants were recov-
ered. Samples were diluted 1:20 in 1 M Tris-HCl, 0.5 M sodium phos-
phate dibasic, 0.05% sodium azide, and Ab40 was detected using the
ELISA as described previously (56).
To simultaneously measure Ab1–40 and Ab1–42 from brain sam-
ples, a bicine-urea gel system of immunoprecipitated Ab was used.
Mouse half-brain was homogenized in 3 ml of 6 M guanidine, 50 mM
Tris-HCl, pH 7.4, at 4 °C. Human Ab was immunoprecipitated with Ab
1153 as described previously (12), and the precipitates were eluted in
bicine gel sample buffer (0.36 M Bistris, 0.16 M bicine, 1% (w/v) SDS,
15% (w/v) sucrose, 2.5% 2-mercaptoethanol) by heating for 10 min at
90 °C. Samples were resolved on 10% acrylamide, 5% bisacrylamide, 8
M urea gels (57, 58) and were blotted to polyvinylidene difluoride mem-
brane. Human Ab was detected using Ab 6E10 at 1:2000 followed by
GAM-IgG conjugated to horseradish peroxidase (1:2000) and ECL sub-
strate (12). Human Ab1–40 and Ab1–42 (Bachem) size standards were
included on the gels.
Data Analysis—Densitometry of immunoblot data was performed
using the Docugel V Scanalytic system (CSP Inc., Billerica, MA). All
results are reported as mean 6 S.E. Statistical significance was deter-
mined using student’s t test analyses (StatView, Abacus Concepts Inc.,
Berkeley, CA). Correlations shown are reported as Pearson product
moment.
RESULTS
Serum TC and ApoE Levels Increase in Response to High
Cholesterol Diet—Serum TC (Table I) was significantly ele-
vated in APP gene-targeted mice fed high dietary cholesterol
when compared with basal diet controls. The range of serum
TC in the high cholesterol diet group was 247–1152 mg/dl.
Conversely, animals maintained on basal diets had levels typ-
ically ranging from 44 to 145 mg/dl. Occasional outliers on the
basal diet were observed (i.e. animal number 061; TC 5 249
mg/dl). In animals fed high dietary cholesterol, liver size and
weight were increased compared with those of mice fed the
TABLE I
Effect of diet on cholesterol and ApoE levels in APP
gene-targeted mice
Data are mean 6 S.E.; n values are shown in parentheses.
Basal diet Cholesterol diet
Liver weight (g) 1.6 6 0.1 (9) 3.7 6 0.1 (20)a
Serum TC (mg/dl) 109.9 6 20.1 (9) 332.5 6 62.4 (20)b
Liver TC (mg/g) 4.1 6 0.3 (5) 70.5 6 5.8 (10)a
Brain TC (mg/g)c 6.1 6 0.6 (5) 7.7 6 0.9 (10)
Frontal cortex TC (mg/g) 13.3 6 0.3 (4) 16.0 6 0.7 (4)b
Serum ApoE (%)d 100.0 6 10.5 (11) 244.1 6 20.9 (16)a
Brain ApoE (%)d 100.0 6 2.8 (7) 112.9 6 4.0 (13)b
Frontal cortex ApoE (%)d 100.0 6 25.3 (4) 237.6 6 25.8 (3)b
a p , 0.0001.
b p , 0.05.
c Values from brain were determined from half-brain samples.
d %, percentage of basal diet mean.
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basal diet (Table I). Mean liver weight increased more than
2-fold in gene-targeted mice as a result of the high cholesterol
diet. Liver-associated TC was dramatically increased more
than 17-fold in mice fed the high cholesterol diet (Table I).
Elevations in serum apoE in response to increases in dietary
cholesterol have been shown to be the result of transcriptional
up-regulation of the apoE gene (59, 60). Serum protein from
gene-targeted mice fed either basal or high dietary cholesterol
was immunoblotted using a mouse apoE-specific antibody. This
antibody recognizes a 34-kDa polypeptide that is clearly absent
in serum from APP gene-targeted mice that also harbor the
apoE-KO (61) locus (APPNLh/NLh, ApoE2/2) (Fig. 1A). A 2.4-
fold increase in mean serum apoE was observed in APP gene-
targeted mice fed the high cholesterol diet (Fig. 1A and Table I).
A strong correlation between serum apoE and TC levels was
found in these mice (r 5 0.86, p , 0.0001).
TC and ApoE Levels Increase in Brain in Response to High
Dietary Cholesterol—TC was extracted from half-brains of APP
gene-targeted mice fed either basal or high cholesterol diets. A
trend toward increased brain TC in mice fed the high choles-
terol diet compared with the basal diet was evident (Table I),
although these results did not reach statistical significance.
However, extraction and measurement of TC from frontal cor-
tices of APP gene-targeted mice fed high cholesterol, as com-
pared with mice on basal diet, revealed a more robust and
statistically significant increase in TC (Table I). Levels of apoE
extracted from half-brains of APP gene-targeted mice fed either
basal or high cholesterol diet were also compared. A small but
statistically significant increase in the levels of brain apoE in
mice fed high dietary cholesterol relative to basal diet controls
was observed (Table I). Levels of brain apoE positively corre-
lated with TC levels (r 5 0.79, p , 0.0001) and with serum
apoE levels (Fig. 1B). A 2.4-fold increase in apoE levels was
observed in the frontal cortex of APP gene-targeted mice fed
the high cholesterol diet relative to those on the basal diet (Fig.
1A and Table I). The differences in the magnitude of the in-
creased TC and apoE when comparing half-brain versus frontal
cortex samples (see Table I) most likely reflected the lower
amount of white matter present in the dissected frontal cortex.
It is likely that white matter-associated lipid dilutes the mag-
nitude of the measured increases in both TC and apoE observed
from half-brain preparations. Also, increased serum cholesterol
and apoE originating from brain blood would not be expected to
significantly contribute to the measured changes of TC and
apoE in brain tissue from mice on the high cholesterol diet,
since blood comprises less than 2% of total brain wet weight.
The increases in brain TC in response to the cholesterol diet
reported here are similar in magnitude to increases observed in
brains from both rat (20) and rabbit (62) following similar high
cholesterol diet regimens. Rabbits also show increased apoE
immunoreactivity in brain following the high cholesterol diet
(63).
No changes in measured phospholipid, total glycerol, and
free fatty acids were observed in the serum or brain of mice fed
basal versus high cholesterol diets (data not shown).
Dietary Cholesterol Reduces Levels of sAPP, but Not Cell-
associated APP, in Brain—Immunoblot and ELISA-based
methods were used to quantify the effects of dietary cholesterol
on APP and its processing derivatives in brain. Tris-soluble
brain homogenates were analyzed on immunoblots using anti-
bodies 6E10 and 54, which recognize secreted sAPPa and
Swedish sAPPb, respectively. Both full-length cell-associated
and secreted APP expressed in the APP gene-targeted mouse
brain are primarily APP695, as previously demonstrated (56).
Mice fed high dietary cholesterol exhibited significant de-
creases in both brain sAPPa (Figs. 2A and 4) and brain sAPPb
(Figs. 2B and 4) relative to mice on the basal diet. Some
variability was observed among individual mice in the magni-
tude of decreases in the sAPPa and sAPPb (Fig. 2). Differences
were attributable to the levels of serum TC attained in mice
within both diet groups. For instance, several mice fed a high
cholesterol diet that showed only subtle increases in serum TC
had only modest decreases in sAPP (i.e. number 784, Fig. 2A).
Conversely, some mice on a basal diet with unexpectedly high
levels of serum TC exhibited more substantial decreases in
sAPP (i.e. number 061, Fig. 2A). A strong negative correlation
was found between levels of serum TC attained and levels of
both brain sAPPa (r 5 20.63; p 5 0.01) and sAPPb (r 5 20.74;
p 5 0.002) when data from both diet groups were combined.
To determine if dietary cholesterol resulted in changes in
cell-associated APP, Tris-insoluble fractions were analyzed for
flAPP and the 12- and 9-kDa COOH-terminal APP cleavage
products that result from cleavage by the b- and a-secretases,
FIG. 1. Mouse serum and brain apoE levels increase in re-
sponse to high dietary cholesterol. A (top), immunoblot of mouse
serum (ser) apoE from APP gene-targeted mice fed either basal or high
cholesterol (chol) diets. Serum from an APP gene-targeted mouse also
harboring the apoE KO locus (labeled as apoE2/2) is devoid of apoE
immunoreactivity. Middle, immunoblot of apoE extracted from frontal
cortex (fr. ctx.) from animals fed either basal or high cholesterol (chol)
diets. Bottom, actin signal from frontal cortex samples. B, correlation of
mouse serum apoE levels to total brain apoE levels from APP gene-
targeted mice on basal or high cholesterol diets, combined (r 5 0.81; p ,
0.0001).
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respectively (12). No significant differences in cell-associated
flAPP in brain resulted from high dietary cholesterol (Figs. 3A
and 4). A trend toward decreased levels of the 12- and 9-kDa
COOH-terminal derivatives due to high cholesterol diet was
noted; however, these effects did not reach statistical signifi-
cance (0.05 , p , 0.15) (Figs. 3B and 4).
Brain Ab1–40 and Ab1–42 Decrease in Response to High
Dietary Cholesterol—Brain Ab from APP gene-targeted mice,
fed either basal or high dietary cholesterol, was analyzed by
two independent methods. Using a sandwich ELISA that spe-
cifically detected Ab1–40 (56), but not Ab17–40 or Ab1–42, a
significant reduction in brain Ab40 was measured in mice fed a
high cholesterol diet (Table II). To determine the effect of the
cholesterol diet on Ab peptide ending at residue 42, a bicine-
urea analysis of immunoprecipitated brain Ab was performed
under conditions previously shown to resolve Ab1–40 and
Ab1–42 (57, 58). As shown in Fig. 5A, both brain Ab1–40 and
Ab1–42 decreased in response to high dietary cholesterol.
Quantitation of these effects revealed highly significant reduc-
tions in both Ab1–40 and Ab1–42 from brains of mice fed high
dietary cholesterol compared with mice on a basal diet (Table
II).
Strong negative correlations of brain Ab levels in gene-tar-
geted mice to several parameters including levels of serum TC,
serum apoE, and brain apoE were evident. Each of these cor-
relations is depicted in Fig. 6 using the Ab40 values obtained
by ELISA (Table II).
Cholesterol Effects on APP Processing Require the Presence of
ApoE—Mice homozygous for a KO apoE locus have been shown
to have elevated levels of serum cholesterol and develop arth-
erosclerotic lesions in blood vessels (61, 64, 91). Mice homozy-
gous for both the targeted APP and the apoE KO loci (APPNLh/
NLh, ApoE2/2) were used to determine the effect of elevated
serum TC, in the absence of apoE, on APP processing in the
mouse brain. APPNLh/NLh, ApoE2/2 mice exhibited signifi-
cantly (p , 0.0001) increased serum TC (mean 542 mg/dl)
relative to APP gene-targeted mice harboring the wild-type
apoE locus (APPNLh/NLh, ApoE1/1) (mean 145 mg/dl). This
FIG. 2. Brain sAPPa and Swedish sAPPb decrease in response
to dietary cholesterol. A, detection of brain sAPPa by antibody 6E10
from APP gene-targeted mice fed either basal or high cholesterol (chol)
diets. B, detection of brain Swedish sAPPb by antibody 54 from APP
gene-targeted mice on the different diets. C, actin immunoreactivity
from samples depicted in A and B. FIG. 3. Full-length APP and COOH-terminal APP processing
derivatives are not significantly altered in brain in response to
dietary cholesterol. A, immunoblot of brain flAPP from APP gene-
targeted mice fed either basal or high cholesterol (chol) diets. B, immu-
noblot of the 12- and 9-kDa COOH-terminal APP processing deriva-
tives. Recombinant C100 (12 kDa) (53) was included on the blot as a size
comparison. C, actin immunoreactivity from samples depicted in A
and B.
FIG. 4. Quantitation of APP and processing fragments from
APP gene-targeted mouse brain in response to dietary choles-
terol. Densitometric analyses of bands for sAPPa, sAPPb, flAPP, and
the 12- and 9-kDa COOH-terminal derivatives are represented as a
percentage of the mean signal from basal diet samples. This allows
comparison across multiple immunoblots. The number (n) of animals
analyzed for each APP fragment was 8 in the basal diet group (f) and
19 in the cholesterol diet group (M). The asterisks denote statistical
significance relative to basal diet groups at p 5 0.007 (sAPPa) and p ,
0.0001 (sAPPb). Other nonsignificant effects had p values greater than
0.1.
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elevation in serum TC was even greater than that generally
observed from APP gene-targeted mice harboring the wild-type
apoE gene when fed high dietary cholesterol (see Table I).
Despite increases in serum TC in APP gene-targeted mice
devoid of apoE, relative to gene-targeted mice wild-type for
apoE, no significant differences in levels of sAPPb (p 5 0.47) or
sAPPa (p 5 0.58) between the two groups were observed (data
not shown). Similarly, no differences in levels of Ab1–40 (p 5
0.88) and Ab1–42 (p 5 0.82) could be attributed to the apoE
genotype (Fig. 5B).
DISCUSSION
Cholesterol and alterations in its homeostasis have been
implicated by several studies to be risk factors in the develop-
ment of AD (46, 48, 49, 62, 65). However, the specific role that
cholesterol might play in AD has not been defined. A potential
link between AD and hypercholesterolemia, a defined risk fac-
tor for coronary artery disease (62, 66, 67), has been proposed.
Other studies have linked decreases in brain cholesterol con-
tent to AD. Brain membranes isolated from AD subjects show
significant decreases in membrane cholesterol content (41, 47).
Furthermore, it has been proposed that inefficient cholesterol
transport resulting from low levels of apoE in the brain may
lead to the loss of synaptic integrity observed in AD (68, 69). In
support of this, apoE levels in brain, cerebrospinal fluid, and
plasma (59, 70–73) of individuals carrying one or two copies of
the apoE4 allele are lower than those with other apoE
genotypes.
Several studies have provided evidence that serum choles-
terol is transported across the blood-brain barrier. Measurable
increases in brain cholesterol have been observed in rodents fed
high cholesterol diets (20, 62). Furthermore, transport of LDL
across the blood brain barrier has been shown to be mediated
by the LDL receptor and has been proposed to be a critical
mechanism by which essential lipids, including cholesterol, are
delivered to brain cells (74). The ability to experimentally mod-
ulate cholesterol levels in both serum and brain of an animal,
taken together with evidence that alterations in cholesterol
metabolism may be involved in AD, has led us to pursue a
potential relationship of cholesterol to APP metabolism using
the APP gene-targeted mouse. Our results demonstrating an
increase in brain cholesterol as a result of high dietary choles-
terol are not only consistent with previous reports (20, 62) but
are also very similar in magnitude. We found that secreted
APP fragments and Ab1–40 and Ab1–42 are modulated in the
brain of the APP gene-targeted mice as a function of cholesterol
levels. Not surprisingly, mice fed either basal or high choles-
terol diets showed some variability in their responsiveness. A
likely explanation for these differences is the efficiency with
which dietary cholesterol is absorbed (75). We demonstrated
that cholesterol and apoE levels, measured in combined data
from animals fed basal and high cholesterol diets, showed
significant negative correlations to levels of brain sAPP and
Ab. Levels of these secreted APP processing fragments were
highly predictive based on measurable changes of both serum
cholesterol and apoE from mice in both the basal and high
cholesterol diet groups. These data support the hypothesis that
the observed changes in sAPP and Ab1–40 and Ab1–42 are a
direct result from cholesterol in the diet as opposed to other
minor differences that may exist between the diet formula-
tions. This is further supported by a lack of change in measured
phospholipid, total glycerol, and free fatty acid in the serum
and brains of mice fed basal versus high cholesterol diets.
The effects of dietary cholesterol on APP derivatives were
most robust on the secretory products of the APP processing
pathway, since no significant changes were observed in cell-
associated full-length APP or in the COOH-terminal deriva-
tives generated by a- and b-secretase processing. There are
several possibilities to explain the observed effects of choles-
terol on secreted APP derivatives in the brain. Increased cel-
lular cholesterol could act to increase membrane rigidity (19)
and thereby decrease accessibility of secretases (a-, b-, and
possibly g-secretase) to APP substrate or to any cofactors as-
sociated with proteolytic activity. Decreases in sAPP secretion,
presumably sAPPa, have been reported in 293 cells when cul-
tured in the presence of increasing concentrations of free cho-
lesterol, and it was suggested that this resulted from reduced
cleavage by the a-secretase due to reduced lateral mobility of
secretase and APP substrate in the membrane (50). Increased
cellular cholesterol has also been demonstrated to inhibit, ei-
ther directly or indirectly, proteolytic cleavage of the SREBP-1
precursor protein, a mechanism to prevent the soluble form of
SREBP-1 from entering the nucleus to up-regulate genes in-
volved in cholesterol synthesis and uptake (26, 76). Further
understanding of the SREBP-1 pathway may provide insight
into the mechanism of the cholesterol-mediated effects on APP
processing.
Alternatively, changes in cellular cholesterol could act to
alter the trafficking of vesicles containing APP to sites where
secretase cleavage occurs or possibly by altering the efficiency
at which secreted APP derivatives or Ab are released from
cells. Cholesterol within the cell is not uniformly distributed.
Plasma membrane contains the highest levels of cholesterol,
while ER and mitochondria contain very little (42, 77). The
Golgi also contains substantial levels of cholesterol, and there
TABLE II
Effect of diet on Ab levels in APP gene-targeted mouse brain
n values are shown in parentheses.
Ab40a Ab1–40b Ab1–42b
ng/mg protein % of basal diet % of basal diet
Basal diet 1.8 6 0.1 (5) 100.0 6 6.2 (9) 100.0 6 12.5 (9)
Cholesterol diet 1.3 6 0.1 (10)c 50.0 6 4.3 (7)d 30.0 6 7.0 (7)d
a Ab40-specific ELISA.
b Bicine-urea gel analysis.
c p 5 0.02.
d p , 0.001.
FIG. 5. Analysis of brain Ab1–40 and Ab1–42 in response to
dietary cholesterol and apoE genotype. A, brains from APP gene-
targeted mice (wild-type for apoE) fed either basal or high cholesterol
(chol) diets were extracted in 6 M guanidine, and Ab was immunopre-
cipitated from extracts as described under “Experimental Procedures.”
Samples were run on bicine-urea gels and immunoblotted with Ab 6E10
to afford resolution and detection of Ab1–40 and Ab1–42. Human
Ab1–40 and 1–42 standards (Bachem) were included on the gels for
comparison. Levels of the 12-kDa signal shown for each sample do not
change in response to dietary cholesterol. The band just above Ab1–40
in each sample comigrates with the Ab1–38 standard (data not shown)
and also decreases in response to cholesterol diet. B, Ab1–40 and
Ab1–42 from brains of APP gene-targeted mice, either wild-type for
apoE (apoE1/1) or KO for apoE (apoE2/2).
Cholesterol Modulates Secreted APP and Ab in Brain16580
is evidence of an increasing gradient in the cis to trans direc-
tion (77, 78). Cholesterol gradients may function in the sorting
of membrane-associated proteins to specific subcellular com-
partments (77). It is therefore possible that alterations in cho-
lesterol content in subcellular membranes could affect the ef-
ficiency at which APP is trafficked along the secretory
pathway, thereby altering cleavage and secretion of APP
derivatives.
In considering a hypothesis where cellular cholesterol regu-
lates APP cleavage or trafficking and secretion, one must rec-
oncile the lack of significant changes in cell-associated full-
length APP and the carboxyl-terminal derivatives. Only a
minority of cell-associated APP is processed for secretion and
subsequently released (79, 80). The majority of cell-associated
APP is trafficked into alternative intracellular pathways, pre-
sumably for ultimate degradation. If the majority of cell-asso-
ciated APP residing in intracellular pathways is largely unaf-
fected by increased cellular cholesterol, then measurable
decreases of cell-associated APP fragments produced in the
secretory pathway would be diluted. Indeed, a trend toward
decreases in the 9- and 12-kDa COOH-terminal derivatives in
brain as a result of elevated cholesterol was observed in APP
gene-targeted mice. Whatever the mechanism, the data re-
ported here indicate that the reciprocal relationship between
sAPPa and Ab described in numerous cell culture systems (i.e.
see Refs. 81–83) does not appear to extend to the cholesterol
effects on these APP processing derivatives in vivo.
Another possible mechanism to explain the cholesterol ef-
fects on secreted APP and Ab that needs to be considered is
increased clearance of these fragments from the brain. ApoE-
lipoprotein complexes are taken up by both astrocytes and
neurons as a means of delivering cholesterol to cells (25, 84,
85). This uptake is mediated by the LDL, LDL receptor-related
protein, and very low density lipoprotein receptors in the brain
(74, 86, 87). It has also been shown that apoE-enriched lipopro-
teins bind Ab and that the LDL receptor mediates uptake of
these complexes into primary neurons and astrocytes (88). Sim-
ilarly, the LDL receptor-related protein receptor mediates up-
take and degradation of secreted APP from the extracellular
space (86). Based on these observations, it is possible that
reduced brain levels of sAPPa, sAPPb, and Ab, all secretory
products of APP processing, may result at least in part from
increased clearance triggered by increased brain apoE and/or
cholesterol levels. However, this mechanism may be less likely,
given that the cholesterol-mediated effects on sAPPa have been
reported in cells cultured in serum-free conditions (50), where
clearance systems are presumably not present.
A cholesterol-cell membrane effect on APP processing or
trafficking and secretion is supported by examining secreted
APP derivatives in APP gene-targeted mice also harboring the
apoE knockout locus. Despite a genetic predisposition to ele-
vated serum cholesterol in APP gene-targeted mice lacking
apoE, no alterations in levels of sAPPa, sAPPb, or Ab1–40 and
Ab1–42 were found compared with APP gene-targeted mice,
wild-type for apoE. Similarly, although absence of apoE has
been shown to dramatically reduce amyloid deposition in trans-
genic PDAPP mice, no differences in APP processing to Ab
could be attributed to absence of apoE (89). Although we cannot
discount the possibility that changes in lipid metabolism that
may occur in the apoE KO mice, other than elevated serum
cholesterol, could impact APP processing in the brain, these
results support the hypothesis that apoE and the cellular up-
take of the apoE-cholesterol complex are required to elicit the
observed changes in the modulation of secreted APP deriva-
tives in brain. An important distinction in this hypothesis to be
emphasized is that despite very high levels of serum cholesterol
attained in the apoE KO mice, an effect on cellular processing
of APP would not be expected. The absence of apoE- lipoprotein
complexes in brain would be predicted to severely impact the
ability of brain cells to take up exogenous sources of cholesterol.
Elucidating the mechanism of changes in cholesterol to APP
metabolism, amyloid deposition, and other pathological fea-
tures observed in the AD brain will be important. Our results
demonstrate a negative relationship between cholesterol levels
and brain apoE levels to secreted APP processing fragments
including Ab1–40 and Ab1–42. It is therefore conceivable that
low steady-state apoE levels that have been documented in
cerebrospinal fluid, plasma, and brains of individuals with at
least one apoE4 allele (59, 70–73) may result in elevations in
Ab1–40 and Ab1–42. To our knowledge, no study has been
reported documenting the effects of apoE genotype on brain Ab
levels in the undiseased brain. Transgenic mice that express
exclusively apoE2, -E3, or -E4 (90) provide mouse model sys-
tems to address the relationship of both cholesterol and apoE
genotype to Ab levels and potentially the progression of AD-
like pathologies in the brain.
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